What is Leerink Partnrs' Estimate for MIRM FY2026 Earnings?

Key Points

• Leerink Partners has increased its FY2026 earnings per share (EPS) estimate for Mirum Pharmaceuticals from $0.50 to $0.57, while the consensus estimate for the current full-year earnings stands at ($1.43) per share.
• Mirum Pharmaceuticals reported a quarterly revenue of $127.79 million, significantly exceeding analyst expectations of $107.91 million and marking a 64.1% year-over-year increase.
• The company's stock is currently rated as a Buy by nine analysts, with a consensus price target of $76.50 following several upgrades from different financial institutions.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Analysts at Leerink Partnrs raised their FY2026 earnings per share (EPS) estimates for Mirum Pharmaceuticals in a research report issued to clients and investors on Wednesday, October 15th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of $0.57 for the year, up from their previous forecast of $0.50. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals' FY2027 earnings at $2.22 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative return on equity of 24.76% and a negative net margin of 13.65%.The company had revenue of $127.79 million for the quarter, compared to analyst estimates of $107.91 million. During the same period last year, the company posted ($0.52) earnings per share. The firm's revenue was up 64.1% compared to the same quarter last year.

MIRM has been the subject of several other reports. Evercore ISI raised their target price on Mirum Pharmaceuticals from $77.00 to $89.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. TD Cowen upgraded Mirum Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, September 25th. HC Wainwright lifted their price target on Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, August 7th. Stifel Nicolaus set a $89.00 price target on Mirum Pharmaceuticals and gave the stock a "buy" rating in a research note on Monday, August 11th. Finally, Cowen began coverage on Mirum Pharmaceuticals in a research note on Wednesday, September 24th. They issued a "buy" rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $76.50.

Mirum Pharmaceuticals Trading Up 4.0%

NASDAQ:MIRM opened at $76.19 on Thursday. The business's 50-day moving average is $72.02 and its two-hundred day moving average is $55.29. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.13 and a quick ratio of 2.97. Mirum Pharmaceuticals has a 12 month low of $36.88 and a 12 month high of $78.54. The firm has a market capitalization of $3.83 billion, a PE ratio of -62.97 and a beta of 0.81.

Insider Transactions at Mirum Pharmaceuticals

In related news, CFO Eric Bjerkholt sold 9,578 shares of the business's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $76.01, for a total transaction of $728,023.78. Following the sale, the chief financial officer owned 39,945 shares of the company's stock, valued at $3,036,219.45. The trade was a 19.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jolanda Howe sold 10,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $58.00, for a total transaction of $580,000.00. Following the completion of the transaction, the senior vice president owned 2,426 shares in the company, valued at approximately $140,708. This trade represents a 80.48% decrease in their position. The disclosure for this sale can be found here. Insiders sold 116,578 shares of company stock worth $7,262,824 in the last three months. 14.36% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of MIRM. CWM LLC grew its holdings in shares of Mirum Pharmaceuticals by 259.4% during the 1st quarter. CWM LLC now owns 593 shares of the company's stock valued at $27,000 after acquiring an additional 428 shares in the last quarter. Comerica Bank grew its holdings in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company's stock valued at $40,000 after acquiring an additional 278 shares in the last quarter. Quarry LP acquired a new stake in shares of Mirum Pharmaceuticals in the 1st quarter valued at $56,000. Osaic Holdings Inc. lifted its stake in shares of Mirum Pharmaceuticals by 46.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company's stock valued at $56,000 after purchasing an additional 351 shares during the last quarter. Finally, KBC Group NV acquired a new stake in shares of Mirum Pharmaceuticals in the 1st quarter valued at $89,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.